Mean age of the participants was 67.8 years, 81% were men, 84% with CCS angina class 3, and about three-quarters had previous CABG and/or PCI. The primary end point was improvement by at least two CCS angina classes at six months. Patients were randomized to device implantation (treatment group) or to a sham procedure (control group). This was a randomized, double-blind, sham-controlled clinical trial conducted at 11 centers and included 104 patients who had Canadian Cardiovascular Society (CCS) class III or IV angina and evidence of reversible myocardial ischemia despite medical therapy for at least 30 days before screening. In this study, the safety and efficacy of the Coronary Sinus Reducer was evaluated in patients with refractory angina on optimal medical therapy who were not candidates for revascularization. Percutaneous reduction of the coronary sinus is an emerging treatment for myocardial ischemia that increases coronary sinus pressure to reduce myocardial ischemia by redistribution of blood from non-ischemic to ischemic myocardium. BackgroundÄespite improvements in medical and surgical treatments of coronary artery disease, there remains a relatively large number of patients with refractory angina. Efficacy of a Device to Narrow the Coronary Sinus in Refractory Angina. Editor's Note: Commentary based on Verheye S, JolicÅ“ur EM, Behan MW, et al.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |